Is Netflix a Must-own Stock?
The early months of 2025 have been very hard on…
Buy
59
BLFS Quote, Financials, Valuation and Earnings
Last price:
$24.95
Seasonality move
:
12.97%
Day range:
$23.88 - $24.91
52-week range:
$16.10 - $29.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
13.10x
P/B ratio:
3.33x
Volume:
455.3K
Avg. volume:
555.7K
1-year change:
44.27%
Market cap:
$1.2B
Revenue:
$82.3M
EPS (TTM):
-$0.45
Analysts' Opinion
-
Consensus RatingBioLife Solutions has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $31.33, BioLife Solutions has an estimated upside of 26.34% from its current price of $24.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing 100% downside risk from its current price of $24.80.
Fair Value
-
According to the consensus of 7 analysts, BioLife Solutions has 26.34% upside to fair value with a price target of $31.33 per share.
BLFS vs. S&P 500
-
Over the past 5 trading days, BioLife Solutions has overperformed the S&P 500 by 7.31% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
BioLife Solutions does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioLife Solutions revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter BioLife Solutions reported revenues of -$3.4M.
Earnings Growth
-
BioLife Solutions earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter BioLife Solutions reported earnings per share of $0.26.
Enterprise value:
1.1B
EV / Invested capital:
--
Price / LTM sales:
13.10x
EV / EBIT:
--
EV / Revenue:
12.32x
PEG ratio (5yr expected):
--
EV / Free cash flow:
219.14x
Price / Operating cash flow:
232.96x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$52M
Return On Assets:
-5.12%
Net Income Margin (TTM):
-23.15%
Return On Equity:
-6.05%
Return On Invested Capital:
-5.7%
Operating Margin:
-40.48%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $76.2M | $84.4M | $87.2M | -$6.1M | -$3.4M | |
| Gross Profit | $46.9M | $46M | $52M | $8.9M | $8.3M | |
| Operating Income | -$10.7M | -$30.6M | -$12.9M | $2.6M | $1.4M | |
| EBITDA | $5.8M | -$18.3M | -$4.4M | $5.4M | $6.7M | |
| Diluted EPS | -$3.29 | -$1.55 | -$0.45 | -$0.33 | $0.26 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $114.7M | $126.1M | $138.5M | $120.6M | $148.8M | |
| Total Assets | $234.8M | $554.3M | $450.2M | $412.7M | $399.5M | |
| Current Liabilities | $15.6M | $42.7M | $44.6M | $42.2M | $32.7M | |
| Total Liabilities | $29.6M | $76.2M | $86M | $75.1M | $50.6M | |
| Total Equity | $205.2M | $478M | $364.2M | $337.7M | $348.9M | |
| Total Debt | $1.3M | $7.2M | $25.6M | $23.8M | $15.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8.5M | -$12.5M | $8.4M | $2.3M | $1.6M | |
| Cash From Investing | -$58.1M | $17.8M | $58.3M | $4M | $73.6M | |
| Cash From Financing | $16.3M | $10.6M | -$6.8M | $9.8M | -$4.1M | |
| Free Cash Flow | -$18.9M | -$18.9M | $4.9M | $1.3M | $583K | |
BLFS
Sector
Market Cap
$1.2B
$36.4M
Price % of 52-Week High
83.94%
44.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
44.27%
-39.12%
Beta (5-Year)
1.933
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$22.61
200-day SMA
Buy
Level
$24.76
Bollinger Bands (100)
Sell
Level
23.85 - 27.61
Chaikin Money Flow
Sell
Level
-26.5M
20-day SMA
Buy
Level
$22.70
Relative Strength Index (RSI14)
Buy
Level
56.23
ADX Line
Buy
Level
24.06
Williams %R
Sell
Level
-1.9439
50-day SMA
Buy
Level
$24.65
MACD (12, 26)
Sell
Level
-0.46
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
88.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (13.7666)
Buy
CA Score
(Annual)
Level (1.1201)
Buy
Beneish M-Score
(Annual)
Level (-2.4707)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.1614)
Buy
Piotroski F Score
(Annual)
Level (8)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Stock Forecast FAQ
In the current month, BLFS has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BLFS average analyst price target in the past 3 months is $31.33.
-
Where Will BioLife Solutions Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioLife Solutions share price will rise to $31.33 per share over the next 12 months.
-
What Do Analysts Say About BioLife Solutions?
Analysts are divided on their view about BioLife Solutions share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioLife Solutions is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is BioLife Solutions's Price Target?
The price target for BioLife Solutions over the next 1-year time period is forecast to be $31.33 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BLFS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioLife Solutions is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BLFS?
You can purchase shares of BioLife Solutions via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioLife Solutions shares.
-
What Is The BioLife Solutions Share Price Today?
BioLife Solutions was last trading at $24.95 per share. This represents the most recent stock quote for BioLife Solutions. Yesterday, BioLife Solutions closed at $24.80 per share.
-
How To Buy BioLife Solutions Stock Online?
In order to purchase BioLife Solutions stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Uber Stock?
In February, Pershing Square manager Bill Ackman revealed that his…
Should You Buy Alibaba Stock Despite the Risks?
Markets rebounded slightly after U.S. President Donald Trump announced a…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 36x
Alerts
Sell
48
FI alert for Apr 25
Fiserv [FI] is up 0.33% over the past day.
Buy
66
FARO alert for Apr 25
Faro Technologies [FARO] is up 0.93% over the past day.
Buy
55
PI alert for Apr 25
Impinj [PI] is up 2.15% over the past day.
